Tripeptide-29: Collagen Stability and Dermal Renewal

Tripeptide-29, chemically also known as Glycylprolylhydroxyproline, is a synthetic mimic of a naturally occurring collagen-building block, composed of the amino acid sequence Gly-Pro-Hyp.⁽¹⁾

This sequence represents one of the fundamental motifs of collagen, a critical structural protein in the extracellular matrix (ECM) of connective tissues. Collagen provides support and scaffolding for cellular complexes and plays an essential role in maintaining the structural integrity of tissues. Tripeptide-29 closely resembles the primary repeating unit of collagen, offering a versatile framework for scientific research into collagen-related.

Image 1: Chemical Structure of Tripeptide-29

Tripeptide-29 is designed to emulate the Gly-Pro-X and Gly-X-Hyp patterns characteristic of collagen’s monomeric subunits, which polymerize into higher-order structures. Its role as a synthetic analogue may allow it to engage in pathways potentially related to collagen synthesis, fiber formation, and extracellular matrix stabilization.

Research suggests that Tripeptide-29 may enhance collagen production, possibly influencing the assembly of the triple-helix structure characteristic of collagen fibers. Additionally, studies hypothesize that the peptide could act as an antioxidant, mitigating oxidative stress within cellular environments, and exert anti-inflammatory, anti-fibrotic, and anti-melanogenic actions, further highlighting its potentially multifaceted biological significance.

 

Research

Tripepetide-29 and Enzymatic Inhibition of DPP-IV

Emerging research suggests that Tripeptide-29 may serve as a peptide inhibitor of dipeptidyl peptidase-IV (DPP-IV), an enzyme involved in the cleavage of dipeptides and tripeptides at the N-terminal end of polypeptides.⁽²⁾ Specifically, Tripeptide-29 appears to inhibit the hydrolysis of the Pro-Hyp bond, a characteristic that aligns with its role as a competitive inhibitor. Studies appear to suggest that the Gly-Pro-Hyp sequence, a prominent motif in collagen hydrolysates, may be a key contributor to DPP-IV inhibition observed in vitro. Notably, Tripeptide-29 was suggested to resist hydrolysis by DPP-IV, indicating it may retain stability and functionality in the presence of this enzyme.

DPP-IV is a serine peptidase expressed on the surface of various cell types, including immune, epithelial, and endothelial cells, as well as in circulation within liver, kidney, and intestinal tissues.⁽³⁾ The enzyme appears to exhibit specificity for smaller peptide substrates, such as glucagon-like peptide-1 (GLP-1), glucose-dependent insulinotropic polypeptide (GIP), and peptide YY (PYY), all of which are implicated in glucose regulation and energy metabolism.⁽⁴⁾

By cleaving GLP-1 and GIP, DPP-IV is hypothesized to mediate their rapid inactivation and clearance, thereby reportedly influencing insulin secretion and glucagon suppression. Inhibiting DPP-IV may potentially elevate levels of active GLP-1 and GIP, possibly contributing to the enhanced insulin secretion, reduced glucagon levels, improved glucose homeostasis, and decreased appetite.⁽⁵⁾ Tripeptide-29’s potential role in this inhibitory pathway underscores its relevance in research related to metabolic regulation.

Tripeptide-29 and Hemostatic Mechanisms

Collagen-related peptides containing the Gly-Pro-Hyp motif, such as Tripeptide-29, are hypothesized to play a role in platelet activation and aggregation via interactions with glycoprotein VI (GPVI) receptors. GPVI, a transmembrane receptor primarily expressed on platelet surfaces, is a key component of the hemostatic process. This receptor belongs to the immunoglobulin superfamily and consists of two subunits: the alpha subunit, which appears to mediate collagen binding, and the beta subunit, which is involved in intracellular signaling pathways. Binding of GPVI to collagen triggers signaling cascades that may activate platelets and facilitate thrombus formation, thereby contributing to blood clotting.

Preliminary research⁽⁶⁾ suggests that Tripeptide-29, a non-cross-linked Gly-Pro-Hyp peptide, might promote the tyrosine phosphorylation of tyrosine kinase Syk and phospholipase C gamma2 (PLCγ2) in platelets. These signaling events are thought to play a role in platelet aggregation, potentially aiding in the cessation or prevention of bleeding. Researchers have reported that the Gly-Pro-Hyp motif within Tripeptide-29 “is sufficient to activate the platelet collagen receptor GPVI,” suggesting its involvement in thrombus formation and hemostatic responses.

Tripeptide-29 and Collagen Stability

Research suggests that Tripeptide-29 may play a pivotal role in maintaining the structural integrity of type I collagen. The hydroxyl (-OH) group of hydroxyproline (Hyp) within the Gly-Pro-Hyp sequence of Tripeptide-29 is hypothesized to contribute to favorable interatomic interactions, potentially stabilizing collagen’s triple-helix structure.⁽⁷⁾ Tripeptide-29 as a monomer may also enhance the stability of collagen microfibrils, with studies indicating a potential role in mitigating UV-induced damage. This stabilization appears to lower the degradation rate of collagen fibers under high-radiation exposure, suggesting protective effects against environmental stressors.⁽⁸⁾

Additionally, investigations into dermal fibroblasts deem suggestive that the antioxidative and anti-glycation properties of collagen hydrolysates rich in Tripeptide-29. Studies report that hydrolyzed type I collagen tripeptides, predominantly Tripeptide-29, may reduce the accumulation of advanced glycation end products (AGEs) and inhibit the generation of denatured collagen. This activity is thought to prevent oxidative damage and preserve the mechanical stability of collagen fibers. The inhibition of AGEs and reactive oxygen species is proposed to slow cellular aging processes by maintaining collagen functionality.⁽⁹⁾

Further in vitro findings suggest that Tripeptide-29 may reduce the activity of matrix metalloproteinases (MMPs), enzymes known to degrade the extracellular matrix, while potentially increase type I collagen synthesis in dermal fibroblasts. The small molecular size of Tripeptide-29 is posited to contribute to its high bioavailability and penetration, potentially amplifying its efficacy in preserving skin matrix integrity. By mitigating oxidative stress, inhibiting collagen degradation, and promoting stability, Tripeptide-29 might offer significant insights into delaying cellular aging and maintaining extracellular matrix health.

Tripeptide-29 and Dermal Aesthetics

Emerging research highlights the potential role of Tripeptide-29 in mitigating age-associated changes in the epidermal layer. Preclinical studies suggest that tripeptides, including Tripeptide-29, may contribute to enhancing skin morphology by promoting hydration, improving elasticity, and reducing structural deformation. Studies suggest that these peptides may also support smoother skin texture and diminish the visual prominence of hyperpigmented areas. Reportedly, experimental findings suggest that approximately 90% of models utilized throughout the research appeared to exhibit increased skin moisturization and improved flexibility, possibly due to enhanced collagen dynamics and structural resilience.

When combined with specific hexapeptides, Tripeptide-29 has been hypothesized to further promote dermal renewal. In preclinical models, formulations containing these peptides appeared to enhance epidermal turnover, potentially reducing the appearance of fine lines, creasing, and skin hollowing. In these investigations, about 50% of laboratory models seem to have exhibited noticeable improvement in skin appearance following twice-daily exposure of peptide-enriched preparations.⁽¹¹⁾

 
NOTE: These products are intended for laboratory research use only. This peptide is not intended for personal use. Please review and adhere to our Terms and Conditions before ordering.

 

References:

1. National Center for Biotechnology Information (2024). PubChem Substance Record for SID 440235153, Tripeptide-29, Source: ChemIDplus. https://pubchem.ncbi.nlm.nih.gov/substance/?source=chemidplus&sourceid=0002239670
2. Hatanaka, T., Kawakami, K., & Uraji, M. (2014). Inhibitory effect of collagen-derived tripeptides on dipeptidylpeptidase-IV activity. Journal of enzyme inhibition and medicinal chemistry, 29(6), 823–828. https://doi.org/10.3109/14756366.2013.858143
3. Trzaskalski, N. A., Fadzeyeva, E., & Mulvihill, E. E. (2020). Dipeptidyl Peptidase-4 at the Interface Between Inflammation and Metabolism. Clinical medicine insights. Endocrinology and diabetes, 13, 1179551420912972. https://doi.org/10.1177/1179551420912972
4. Kieffer, T. J., McIntosh, C. H., & Pederson, R. A. (1995). Degradation of glucose-dependent insulinotropic polypeptide and truncated glucagon-like peptide 1 in vitro and in vivo by dipeptidyl peptidase IV. Endocrinology, 136(8), 3585–3596. https://doi.org/10.1210/endo.136.8.7628397
5. Kasina, S. V. S. K., & Baradhi, K. M. (2022). Dipeptidyl Peptidase IV (DPP IV) Inhibitors. In StatPearls. StatPearls Publishing. https://pubmed.ncbi.nlm.nih.gov/31194471/
6. Asselin J, Knight CG, Farndale RW, Barnes MJ, Watson SP. Monomeric (glycine-proline-hydroxyproline)10 repeat sequence is a partial agonist of the platelet collagen receptor glycoprotein VI. Biochem J. 1999 Apr 15;339 ( Pt 2)(Pt 2):413-8. PMID: 10191274; PMCID: PMC1220172. https://pubmed.ncbi.nlm.nih.gov/10191274/
7. Némethy G, Scheraga HA. Stabilization of collagen fibrils by hydroxyproline. Biochemistry. 1986 Jun 3;25(11):3184-8. doi: 10.1021/bi00359a016. PMID: 3730354. https://pubmed.ncbi.nlm.nih.gov/3730354/
8. Jariashvili, K., Madhan, B., Brodsky, B., Kuchava, A., Namicheishvili, L., & Metreveli, N. (2012). UV damage of collagen: insights from model collagen peptides. Biopolymers, 97(3), 189–198. https://doi.org/10.1002/bip.21725
9. Lee, Y. I., Lee, S. G., Jung, I., Suk, J., Lee, M. H., Kim, D. U., & Lee, J. H. (2022). Effect of a Collagen Tripeptide on Antiaging and Inhibition of Glycation of the Skin: A Pilot Study. International journal of molecular sciences, 23(3), 1101. https://doi.org/10.3390/ijms23031101
10. Garre, G. Martinez-Masana, J. Piquero-Casals, and C. Granger, “Redefining face contour with a novel anti-aging cosmetic product: an open-label, prospective clinical study,” Clin. Cosmet. Investig. Dermatol., vol. 10, pp. 473–482, 2017. https://pmc.ncbi.nlm.nih.gov/articles/PMC5691901/
11. Reivitis A, Karimi K, Griffiths C, Banayan A. A single-center, pilot study evaluating a novel TriHex peptide- and botanical-containing eye treatment compared to baseline. J Cosmet Dermatol. 2018 Jun;17(3):467-470. doi: 10.1111/jocd.12542. Epub 2018 Apr 16. PMID: 29663676. https://pubmed.ncbi.nlm.nih.gov/29663676/
12. Image 1 source: National Center for Biotechnology Information (2024). PubChem Substance Record for SID 440235153, Tripeptide-29, Source: ChemIDplus. https://pubchem.ncbi.nlm.nih.gov/substance/?source=chemidplus&sourceid=0002239670